|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-8-5
|
|
pubmed:abstractText |
A highly specific antibody against recombinant human dihydropyrimidine dehydrogenase (DPD) has been developed to immunohistochemically assess DPD expression in tumors. A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2997-3001
|
|
pubmed:meshHeading |
pubmed-meshheading:16080558-Adenocarcinoma, Scirrhous,
pubmed-meshheading:16080558-Adult,
pubmed-meshheading:16080558-Aged,
pubmed-meshheading:16080558-Antibodies,
pubmed-meshheading:16080558-Antibody Specificity,
pubmed-meshheading:16080558-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:16080558-Drug Combinations,
pubmed-meshheading:16080558-Female,
pubmed-meshheading:16080558-Fluorouracil,
pubmed-meshheading:16080558-Humans,
pubmed-meshheading:16080558-Immunohistochemistry,
pubmed-meshheading:16080558-Male,
pubmed-meshheading:16080558-Middle Aged,
pubmed-meshheading:16080558-Oxonic Acid,
pubmed-meshheading:16080558-Pyridines,
pubmed-meshheading:16080558-Recombinant Proteins,
pubmed-meshheading:16080558-Retrospective Studies,
pubmed-meshheading:16080558-Stomach Neoplasms,
pubmed-meshheading:16080558-Tegafur
|
|
pubmed:articleTitle |
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
|
|
pubmed:affiliation |
Department of Internal Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan. tosshimi@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article
|
